February 29, 2012
Volume 7 - Issue 9            

DynaMed Weekly Update

For the week ending February 24, 2012  

Last week 260 articles were evaluated via DynaMed's Systematic Literature Surveillance and 169 were added to DynaMed content. 

Based on the editors' criteria of selecting "articles most likely to change clinical practice," one article of significant interest was selected for the DynaMed Weekly Update.

Feature Articles

Intramuscular Midazolam May Be More Effective than IV Lorazepam for Prehospital Seizure Cessation


Treatment with an intravenous (IV) benzodiazepine, most commonly lorazepam, is the preferred first line treatment for prolonged epileptic seizures in the emergency department, but IV medication can be difficult for first responders to administer. An alternative is for paramedics to give intramuscular midazolam in place of IV drugs and this treatment is commonly used, due to its speed and relative simplicity of administration. The RAMPART randomized trial compared intramuscular midazolam vs. IV lorazepam given by paramedics prior to hospital arrival in 893 children and adults with seizures lasting for > 5 minutes that persisted after the arrival of the paramedics. Doses were midazolam 10 mg or lorazepam 4 mg for adults and children > 40 kg (88 lbs), and midazolam 5 mg or lorazepam 2 mg for smaller children. Blinding was maintained by the use of IV placebo for the midazolam group and intramuscular placebo for the lorazepam group. Patients were excluded for major trauma, hypoglycemia, cardiac arrest, heart rate < 40 beats per minute, pregnancy, known allergy to intervention, or estimated weight < 13 kg (28.6 lbs).


The randomized intervention was given to 99% of the midazolam group, but only 63% of the lorazepam group. Of those not receiving lorazepam, convulsions stopped prior to treatment in 64%, and paramedics failed to start the IV in 28%. All randomized patients were included in an intention-to-treat analysis. Seizures were terminated without need for rescue medication in 73.4% for intramuscular midazolam vs. 63.4% for IV lorazepam (p < 0.001, NNT 10) (level 2 [mid-level] evidence). Intramuscular midazolam was associated with lower rates of hospitalization (57.6% vs. 65.6%, p < 0.05, NNT 13) and intensive care admission (28.6% vs. 36.2%, p < 0.05, NNT 14). There were no significant differences in endotracheal intubation within 30 minutes or seizure recurrence within 12 hours of emergency department arrival. Similar results were obtained in per-protocol analyses. (N Engl J Med 2012 Feb 16;366(7):591).


For more information, see the Status epilepticus topic in DynaMed.


Presenting the Benefits of Surgery in Terms of Absolute Risk instead of Relative Risk Appears to Decrease the Likelihood of Patients Electing Surgery


A recent randomized trial investigated how different approaches to explaining the benefits of surgery may affect patients' likelihood of choosing to have surgery. A total of 420 adults attending an appointment at a neurology clinic for reasons unrelated to carotid artery disease were randomized to view a 30-second video presentation describing treatment options in a hypothetical clinical scenario of asymptomatic 70% carotid artery stenosis. The videos used 1 of 5 methods to describe how much the risk of stroke would be reduced by the addition of surgery to best medical therapy. These descriptions were: 50% relative risk reduction over 5 years; absolute risk of stroke at 5 years of 5% with surgery vs. 11% without surgery; absolute 5-year event-free survival of 95% vs. 89%; annualized absolute risk of 1% vs. 2% per year; or a qualitative description ("risk significantly less" without numerical presentation). The sex and race of the video presenter were also randomized, giving a total of 20 different scenarios. After the video, participants completed a survey regarding treatment choice of surgery plus medication vs. medication alone. No participants had any history of carotid stenosis.


About half of the participants reported that they would choose surgery plus medication, but the likelihood of choosing surgery varied with presentation method. Participants who saw videos explaining the benefits of surgery in terms of absolute risk reduction were significantly less likely to choose surgery than were those viewing the relative risk and qualitative conditions (p < 0.001) (level 3 [lacking direct] evidence). Surgery was chosen by 63% for relative risk reduction, 43% for absolute risk, 37% for absolute event-free survival, 35% for annualized absolute risk, and 64% for qualitative presentation. Sex and race of the presenter were not associated with treatment choice (Neurology 2012 Jan 31;78(5):315).


These data may help clinicians better understand how patients' choices can be affected by how their treatment options are framed.


For more information, see the Carotid artery stenosis repair topic in DynaMed.



Click Here to Earn CME credit Earn Credit for Reading this e-Newsletter

 For more information on this educational activity, see the CME sidebar.
New topic added to DynaMed this week
Call for Peer Reviewers

We are currently seeking reviewers for: 

Huntington disease

Neuromyelitis optica (NMO) 

Progressive multifocal leukoencephalopathy (PML)  


Learn more about the DynaMed Contribution Opportunities:

DynaMed Peer Review 

Editorial Policies for Reviewers 

About DynaMed Weekly Update

Prepared by the clinician members of the DynaMed Editorial Team, DynaMed Weekly Update is a compilation of one to five articles selected from DynaMed's Systematic Literature Surveillance as articles most likely to change clinical practice.

DynaMed   EP Point-of-Care Resources

Free Weekly Update Subscription Free Newsletter Subscription

Share with Colleagues

Send CommentsSend Comments




Print Printable View

DynaMed Events

DynaMed iconDynaMed Free Trial 
CME Information


0.25 AMA PRA Category I Credit(s)™
Family Physicians: 0.25 Prescribed credits
Nurse Practitioners: 0.25 Contact hours
Release Date: February 29, 2012 
Expiration Date: February 28, 2013
Estimated Completion Time:
15 minutes
There is no fee for this activity.

To Receive Credit 
In order to receive your certificate of participation, you should read the information about this activity, including the disclosure statements, review the entire activity, take the post-test, and complete the evaluation form. You may then follow the directions to print your certificate of participation. To begin, click the CME icon at the end of the article.

Program Overview

Learning Objectives

Upon successful completion of this educational program, the reader should be able to:
1. Discuss the significance of this article as it relates to your clinical practice.
2. Be able to apply this knowledge to your patient's diagnosis, treatment and management.
Faculty Information
Alan Ehrlich, MD - Assistant Clinical Professor in Family Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA; Deputy Editor, DynaMed, Ipswich, Massachusetts, USA

Michael Fleming, MD, FAAFP - Assistant Clinical Professor of Family Medicine and Comprehensive Care, LSU Health Science Center School of Medicine, Shreveport, Louisiana, USA; Assistant Clinical Professor of Family Medicine, Department of Family and Community Medicine, Tulane University Medical School, New Orleans, Louisiana, USA; Chief Medical Officer, Amedisys, Inc. & Antidote Education Company

Dr. Ehrlich, Dr. Fleming, DynaMed Editorial Team members, and the staff of Antidote Education Company have disclosed that they have no relevant financial relationships or conflicts of interest with commercial interests related directly or indirectly to this educational activity.
No commercial support has been received for this activity.

Accreditation Statements

ACCME This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Antidote Education Company and EBSCO Publishing. Antidote is accredited by the ACCME to provide continuing medical education for physicians.  Antidote Education Company designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AAFP: This activity, DynaMed Weekly Update 2011, has been reviewed and is acceptable for up to 13 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins March 2, 2011. Term of approval is for one year from this date. Each Weekly Update is approved for 0.25 Prescribed credits. Credit may be claimed for one year from the date of each Weekly Update.


AANP: This program is approved for 0.25 contact hour of continuing education by the American Academy of Nurse Practitioners.  

Program ID 1102071Z.

Copyright 2010 EBSCO Publishing. All rights reserved.